Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Clin Ter ; 162(4): 331-41, 2011.
Artigo em Italiano | MEDLINE | ID: mdl-21912821

RESUMO

INTRODUCTION: The present study aims to evaluate effectiveness of antipsychotics in a cohort of chronic outpatients affected by schizophrenia and related disorders. MATERIALS AND METHODS: Three hundred chronic patients affected by schizophrenia (n=173), schizoaffective (n=117) and delusional (n=60) disorder who were in treament with antipsychotics on 1.3.2008 were considered in the study; effectiveness of antipsychotic treatment was evaluated by means of rates of all cause discontinuation in a 12 months period (31.3.2008-31.3.2009) and of "overall duration of treatment" (DT) (duration of treatment retrospectively evaluated on the basis of clinical records+duration of treatment prospectively evaluated during the 12-months follow up). RESULTS: Discontinuation of treatment was registered in 25% of patients (29% due to side effects, 14% due to scarce adherence, 11% due to lack of efficacy, 22% due to more causes). Clozapine (7%), Risperidon Long-acting (10%), Typical Antipsychotics depot (11%) and Olanzapine were associated to lower rates of all causes discontinuation. Overall mean duration of antipsychotic treatment was 18± 32 months, with statistically significant differences between drugs (F=4.65, p=0.000). Clozapine (65 mo), Olanzapine (50 mo), butyrophenones (49 mo), typical antipsychotics depot (48 mo), and risperidone (47.5 mo) were the antipsychotics with a longer duration of treatment. Only Clozapine showed a significantly longer DT than any other antipsychotic medication excluding buthyrrohenones. CONCLUSIONS: Rates of all cause discontinuation of antipsychotics appear to be somewhat lower than expected on the basis of pragmatic studied published in the last years; similarly overall duration of treatment seems to be longer. Clozapine is associated to a higher overall effectiveness respect to any other atypical antipsychotic.


Assuntos
Antipsicóticos/uso terapêutico , Delusões/tratamento farmacológico , Transtornos Psicóticos/tratamento farmacológico , Esquizofrenia/tratamento farmacológico , Adulto , Antipsicóticos/administração & dosagem , Antipsicóticos/efeitos adversos , Benzodiazepinas/administração & dosagem , Benzodiazepinas/efeitos adversos , Benzodiazepinas/uso terapêutico , Butirofenonas/administração & dosagem , Butirofenonas/efeitos adversos , Butirofenonas/uso terapêutico , Clozapina/administração & dosagem , Clozapina/efeitos adversos , Clozapina/uso terapêutico , Preparações de Ação Retardada , Dibenzotiazepinas/administração & dosagem , Dibenzotiazepinas/efeitos adversos , Dibenzotiazepinas/uso terapêutico , Quimioterapia Combinada , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Olanzapina , Pacientes Desistentes do Tratamento , Estudos Prospectivos , Fumarato de Quetiapina , Estudos Retrospectivos , Risperidona/administração & dosagem , Risperidona/efeitos adversos , Risperidona/uso terapêutico , Adulto Jovem
2.
Acta Neurol (Napoli) ; 15(6): 433-41, 1993 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-8160555

RESUMO

Sixty-nine cases of Optic Neuritis were studied in order to evaluate the percentage of evolution into multiple sclerosis. We observed an incidence rate of 53.6% which is somewhat high respect to data present in literature. The various findings obtained in the present study were compared with those of the literature and the similarities and discrepancies underlined.


Assuntos
Esclerose Múltipla/complicações , Esclerose Múltipla/epidemiologia , Neurite Óptica/complicações , Neurite Óptica/epidemiologia , Adolescente , Adulto , Fatores Etários , Criança , Métodos Epidemiológicos , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Neurite Óptica/fisiopatologia , Dor , Fatores Sexuais , Visão Ocular
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...